← Back to Search

Cognitive Measures Comparison for Alzheimer's Disease Prevention (NoMAD Trial)

N/A
Waitlist Available
Led By Terry E. Goldberg, Ph.D.
Research Sponsored by New York State Psychiatric Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
English speaking participants, ages 60-85 years
Be older than 18 years old
Must not have
Active treatment of cancer
Use of antidepressants with large anticholinergic properties will be excluded. These include: amitriptyline, amoxapine, clomipramine, desipramine, doxepin, imipramine, isocarboxazide, lithium, maprotiline, mirtazapine, nortriptyline, tranylcypromine trimipramine, and phenelzine.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 52; change in score will be assessed
Awards & highlights

Summary

This trial will compare new measures of cognition and everyday function to established ones, in order to see which are more effective.

Who is the study for?
This trial is for English-speaking individuals aged 60-85 with memory concerns but no severe cognitive impairment (MMSE score ≥24). They must have a reliable informant and meet certain education-specific memory criteria. Excluded are those with significant neurological diseases, untreated diabetes, active cancer treatment, or using specific antidepressants.Check my eligibility
What is being tested?
The study compares novel cognitive and functional measures designed to prevent Alzheimer's disease against established ones over one year. Participants will be randomly assigned to either the new tests or traditional ones to see which better detects changes in cognition and daily function.See study design
What are the potential side effects?
Since this trial involves cognitive testing rather than medication, there are no direct side effects from drugs. However, participants may experience fatigue or stress related to frequent testing.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 60 and 85 years old and speak English.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently receiving treatment for cancer.
Select...
I am not taking antidepressants known for strong anticholinergic effects.
Select...
I have been diagnosed with a major psychiatric disorder and/or have a current issue with alcohol or substance use.
Select...
I am a pre-menopausal woman and I am pregnant.
Select...
I have had a stroke or am at high risk for heart disease.
Select...
I have a neurological condition like MS, epilepsy, or significant brain injury.
Select...
I have diabetes that has not been treated.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 52; change in score will be assessed
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 52; change in score will be assessed for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Computerized Functional Assessment Scale (CFAS).
No Practice Effect (NPE) Cognitive Battery.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Novel measures of cognition and everyday functionExperimental Treatment1 Intervention
No Practice Effects (NPE) cognitive battery Miami Computerized Functional Assessment Scale (CFAS) Participants will receive three serial assessments of the NPE and CFAS over a one year period. Assessments will take place at baseline, week 12, and week 52.
Group II: Established measures of cognition and everyday functionActive Control1 Intervention
Preclinical Alzheimer's Cognitive Composite (PACC) Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) Functional Assessment Questionnaire (FAQ). Participants will receive three serial assessments of the PACC, ADAS-Cog and FAQ over a one year period. Assessments will take place at baseline, week 12, and week 52.

Find a Location

Who is running the clinical trial?

Columbia UniversityOTHER
1,448 Previous Clinical Trials
2,531,090 Total Patients Enrolled
Feinstein Institute for Medical ResearchOTHER
21 Previous Clinical Trials
5,272 Total Patients Enrolled
University of MiamiOTHER
918 Previous Clinical Trials
412,229 Total Patients Enrolled

Media Library

No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS) Clinical Trial Eligibility Overview. Trial Name: NCT03900273 — N/A
Healthy Subjects Research Study Groups: Novel measures of cognition and everyday function, Established measures of cognition and everyday function
Healthy Subjects Clinical Trial 2023: No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS) Highlights & Side Effects. Trial Name: NCT03900273 — N/A
No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03900273 — N/A
Healthy Subjects Patient Testimony for trial: Trial Name: NCT03900273 — N/A
~62 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top